J.P. Morgan Downgrades DexCom(DXCM.US) to Hold Rating, Cuts Target Price to $85

摩根大通下调德康医疗(DXCM.US)至持有评级，下调目标价至85美元

moomoo资讯 · 2024/10/26 10:31 · 评级/大行评级

J.P. Morgan analyst Robbie Marcus downgrades $DexCom (DXCM.US)$ to a hold rating, and adjusts the target price from $145 to $85.

According to TipRanks data, the analyst has a success rate of 55.7% and a total average return of 10.7% over the past year.

AnalystRecentRatingAutoNews_206019_20241025_99afc3b527b6e397d30d2fd051a5d4ee10a4b113_1729963860072963_mm_en

Furthermore, according to the comprehensive report, the opinions of $DexCom (DXCM.US)$'s main analysts recently are as follows:

DexCom's recent quarterly report has reinforced investor confidence in its 2025 revenue target, which incorporates a conservative projection from Stelo. It is anticipated that the company's earnings estimates may see an upward revision with the return to double-digit revenue growth.
DexCom's Q3 revenue exceeded expectations due to a record number of new patient starts, while earnings were influenced by reduced gross margins. The company is gaining momentum as the year ends, and there is a clear perspective for achieving at least 15% year-over-year growth in 2025.
DexCom's third-quarter sales surpassed expectations, bolstered by stronger-than-anticipated international performance, despite U.S. sales not meeting the general market predictions. This discrepancy is partially ascribed to the reduced number of new patients observed in the second quarter, coupled with anticipated effects from product mix variations. The company's forecast for sales and margins in 2024, along with its objectives for 2025, remain unchanged.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

摩根大通分析师Robbie Marcus下调$德康医疗 (DXCM.US)$至持有评级，并将目标价从145美元下调至85美元。

根据TipRanks数据显示，该分析师近一年总胜率为55.7%，总平均回报率为10.7%。

AnalystRecentRatingAutoNews_206019_20241025_99afc3b527b6e397d30d2fd051a5d4ee10a4b113_1729963860072963_mm_sc

此外，综合报道，$德康医疗 (DXCM.US)$近期主要分析师观点如下：

德康医疗最近的季度报告已经加强了投资者对其2025年营业收入目标的信心，该目标包括Stelo的保守预测。预计随着恢复到两位数的营业收入增长，公司的盈利预估可能会出现上调。
德康医疗第三季度的营收超出预期，这主要归因于创纪录的新患者数量增长，而收益受到毛利率降低的影响。公司在年底增长势头强劲，明确了2025年至少实现15%年增长的前景。
德康医疗第三季度的销售业绩超出预期，受到比预期更强的国际业绩支撑，尽管美国销售未达到整体市场预测。这种差异部分归因于观察到的二季度新患者数量减少，以及产品组合变化的预期效果。公司对2024年的销售额和毛利的预测，以及其对2025年的目标，均保持不变。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

J.P. Morgan Downgrades DexCom(DXCM.US) to Hold Rating, Cuts Target Price to $85

J.P. Morgan Downgrades DexCom(DXCM.US) to Hold Rating, Cuts Target Price to $85

风险及免责提示

声明